Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty
-
Lauren A. Ray
,
George J. Eckert
Abstract
Objectives
The histrelin implant has been used to treat central precocious puberty (CPP) for more than 15 years. Although approved for annual use, limited published reports suggest that a single implant is efficacious well beyond a year. Our objective was to report our long-term experience using a single histrelin implant for more than 12 months in children with CPP.
Methods
We performed a retrospective study of 170 children with central precocious puberty treated with a single histrelin implant for more than 1 year.
Results
Implants were left in situ for an average of 24 months. Pubertal development regressed or remained stable in the vast majority of patients and biochemical suppression was maintained. No correlation between time since an implant was placed and complications such as implant breakage or a second incision was seen.
Conclusions
A single histrelin implant provides excellent pubertal suppression well beyond a year. Extended use of a single histrelin implant should be considered standard of care in children with CPP.
-
Research funding: None declared.
-
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: Not applicable.
-
Ethical approval: The local Institutional Review Board deemed the study exempt from review.
References
1. Chen, M, Eugster, EA. Central precocious puberty: update on diagnosis and treatment. Paediatr Drugs 2015;17:273–81. https://doi.org/10.1007/s40272-015-0130-8.Suche in Google Scholar PubMed PubMed Central
2. Hirsch, HJ, Gillis, D, Strich, D, Chertin, B, Farkas, A, Lindenberg, T, et al.. The histrelin implant: a novel treatment for central precocious puberty. Pediatrics 2005;116:e798–802. https://doi.org/10.1542/peds.2005-0538.Suche in Google Scholar PubMed
3. Lewis, KA, Goldyn, AK, West, KW, Eugster, EA. A single histrelin implant is effective for 2 years for treatment of central precocious puberty. J Pediatr 2013;163:1214–6. https://doi.org/10.1016/j.jpeds.2013.05.033.Suche in Google Scholar PubMed PubMed Central
4. Rahhal, S, Clarke, WL, Kletter, GB, Lee, PA, Neely, EK, Reiter, EO, et al.. Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty. Int J Pediatr Endocrinol 2009;2009:e812517. https://doi.org/10.1155/2009/812517.Suche in Google Scholar PubMed PubMed Central
5. Greulich, WW, Pyle, SI. Radiographic atlas of skeletal development of the hand and wrist, 2nd ed. Stanford: Stanford University Press; 1959.10.1097/00000441-195909000-00030Suche in Google Scholar
6. Bangalore Krishna, K, Fuqua, JS, Rogol, AD, Klein, KO, Popovic, J, Houk, CP, et al.. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr 2019;91:357–72. https://doi.org/10.1159/000501336.Suche in Google Scholar PubMed
7. Lupkin, S. Hormone blocker sticker shock: kids drug costs 8 times more than one for adults; 2020. Available from: https://www.npr.org/sections/health-shots/2020/02/24/808049526/hormone-blocker-sticker-shock-kids-drug-costs-8-times-more-than-one-for-adults [Accessed 29 Jul 2022].Suche in Google Scholar
8. Davis, JS, Alkhoury, F, Burnweit, C. Surgical and anesthetic considerations in histrelin capsule implantation for the treatment of precocious puberty. J Pediatr Surg 2014;49:807–10. https://doi.org/10.1016/j.jpedsurg.2014.02.067.Suche in Google Scholar PubMed
9. Silverman, LA, Neely, EK, Kletter, GB, Lewis, K, Chitra, S, Terleckyj, O, et al.. Long-term continuous suppression with once-yearly histrelin subcutaneous implants for the treatment of central precocious puberty: a final report of a phase 3 multicenter trial. J Clin Endocrinol Metab 2015;100:2354–63. https://doi.org/10.1210/jc.2014-3031.Suche in Google Scholar PubMed PubMed Central
10. Villalta, D, Quintos, JB. Gonadotropin suppression for 7 years after a single histrelin implant for precocious puberty. J Endocr Soc 2022;6:bvab189. https://doi.org/10.1210/jendso/bvab189.Suche in Google Scholar PubMed PubMed Central
© 2023 Walter de Gruyter GmbH, Berlin/Boston
Artikel in diesem Heft
- Frontmatter
- Editorial
- Thyroid – what is a healthy thyroid function test?
- Review
- Thyroid storm in pediatrics: a systematic review
- Opinion Paper
- DSD/intersex: historical context and current perspectives
- Original Articles
- Predictive value of 6 h postoperative parathyroid hormone level on permanent hypoparathyroidism in pediatric total thyroidectomy: a pilot study
- Evaluation of a nurse-led counselling intervention on selected outcome variables for parents of children with congenital adrenal hyperplasia
- The relationship between estrogen and subsequent growth restriction among adolescents with heavy menstrual bleeding at menarche
- An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment
- Normal bone density but altered geometry in girls with Turner syndrome
- Newborn screening for inborn errors of metabolism in a northern Chinese population
- Evaluation of serum telomerase activity in normal-weight young girls with polycystic ovary syndrome and its relation to metabolic parameters
- Early onset of puberty during COVID-19 pandemic lockdown: experience from two Pediatric Endocrinology Italian Centers
- Using change in predicted adult height during GnRH agonist treatment for individualized treatment decisions in girls with central precocious puberty
- Short Communications
- Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty
- Relationships among biochemical measures in children with diabetic ketoacidosis
- Case Reports
- Hyperthyroidism in McCune–Albright Syndrome – a case report
- Sexual precocity in the setting of parental use of a compounded testosterone cream: case report and review of the literature
- Intracardiac thrombosis following intravenous zoledronate treatment in a child with steroid-induced osteoporosis
- Identification of a novel mutation in the ALDOB gene in hereditary fructose intolerance
Artikel in diesem Heft
- Frontmatter
- Editorial
- Thyroid – what is a healthy thyroid function test?
- Review
- Thyroid storm in pediatrics: a systematic review
- Opinion Paper
- DSD/intersex: historical context and current perspectives
- Original Articles
- Predictive value of 6 h postoperative parathyroid hormone level on permanent hypoparathyroidism in pediatric total thyroidectomy: a pilot study
- Evaluation of a nurse-led counselling intervention on selected outcome variables for parents of children with congenital adrenal hyperplasia
- The relationship between estrogen and subsequent growth restriction among adolescents with heavy menstrual bleeding at menarche
- An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment
- Normal bone density but altered geometry in girls with Turner syndrome
- Newborn screening for inborn errors of metabolism in a northern Chinese population
- Evaluation of serum telomerase activity in normal-weight young girls with polycystic ovary syndrome and its relation to metabolic parameters
- Early onset of puberty during COVID-19 pandemic lockdown: experience from two Pediatric Endocrinology Italian Centers
- Using change in predicted adult height during GnRH agonist treatment for individualized treatment decisions in girls with central precocious puberty
- Short Communications
- Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty
- Relationships among biochemical measures in children with diabetic ketoacidosis
- Case Reports
- Hyperthyroidism in McCune–Albright Syndrome – a case report
- Sexual precocity in the setting of parental use of a compounded testosterone cream: case report and review of the literature
- Intracardiac thrombosis following intravenous zoledronate treatment in a child with steroid-induced osteoporosis
- Identification of a novel mutation in the ALDOB gene in hereditary fructose intolerance
